Apex Dermatology Institute


    Psoriasis is a chronic relapsing immune mediated skin inflammatory disease characterized by epidermal thickening, keratinocyte hyperproliferation, dilated blood vessels and abnormal differentiation of cells. It is a common disease with a prevalence of up to 2–3% in many populations. Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (inflammation and swelling of the small joints of the hands and feet,knees etc). Patients may have itchy scaly erythematous plaques especially over scalp, extensor surfaces over joints or even develop into erythroderma in severe cases.

    Diagnosis is often established by clinical features. Treatment choices mainly depend on disease severity and patients comorbidity. Topical steroids and vitamin D analogue are usually suitable for mild psoriasis. Patients with more severe cases may be given oral systemic medications including immunosuppresants. Biologics, including Tumour necrosis factor alpha(TNF-α) antagonists (anti-TNF) or various interleukin antagonists are breakthrough treatment options in recent years which provide satisfactory response with less systemic side effects.

    Common types of Psoriasis:

  • Plaque Psoriasis
  • Guttate Psoriasis
  • Pustular Psoriasis
  • Erythrodermic Psoriasis
  • Psoriatic nails

  • Psoriasis of the Scalp
  • Palmoplantar psoriasis
  • Mucosal Psoriasis
  • Psoriatic arthritis (PsA)

  • psoriasis hong kong

    Medical Therapy for Psoriasis

      For patients with moderate or severe psoriasis, using biologics can help to clear your skin. Biologics are made from proteins, they can effectively target the immune response that leads to the skin proliferation of psoriasis. Below are some biologics available at our clinic:



      1. Guselkumab (Tremfya) is a biologic that selectively blocks interleukin-23 (IL-23), one of the key proteins thought to be responsible for the symptoms of plaque psoriasis. It is used to treat adults with moderate to severe plaque psoriasis.


      2. Ixekizumab (Taltz) is a biologic that selectively blocks interleukin-17A (IL-17A). It is used to treat adults with moderate to severe plaque psoriasis.


      3. Secukinumab (Cosentyx) is a fully human monoclonal antibody that selectively targets Human Interleukin 17A (IL-17A) and neutralizes the bioactivity of this cytokine. IL-17A is a natural protein produced by a T helper cells in human body that are pro-inflammatory and its overproduction can trigger autoimmune diseases. This medication works by blocking selectively on IL-17A (Interleukin-17A) that may cause inflammation and swelling.

      Secukinumab is used to treat adults with moderate to severe plague psoriasis that involves large areas or many areas of the body, as well as active psoriatic arthritis and ankylosing spondylitis.

      This medication is given by injection under your skin (subcutaneous injection) in the upper arms, thighs, or abdomen area. The recommended dose of secukinumab for plaque psoriasis is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4. Majority of clinical trial participants achieved clear or almost clear skin at 12 weeks.

      Public Education in the Media